Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

A risk-adapted approach to acute GVHD treatment: are we there yet?

Bone Marrow Transplantation volume 51, pages 172–175 (2016)Cite this article

Subjects

Abstract

Acute GVHD (aGVHD) is an immunologic complication of allogeneic hematopoietic cell transplantation (HCT) that can range from mild to life-threatening. Models to predict patients at risk of poor outcomes have been developed using both clinical and laboratory data, and the time to test these models in clinical trials has arrived. However, each modeling method has its potential advantages and limitations. In this mini-review, we summarize recent refinements to these models. We also suggest avenues for improving risk stratification through further studies of a patient’s healing capacity and predisposition to endothelial damage, two factors that impact aGVHD outcomes but are absent from the current risk stratification models.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Weisdorf D, Haake R, Blazar B, Miller W, McGlave P, Ramsay N et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 1990; 75: 1024–1030.

    CAS  PubMed  Google Scholar 

  2. Martin PJ, Schoch G, Fisher L, Byers V, Anasetti C, Appelbaum FR et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76: 1464–1472.

    CAS  PubMed  Google Scholar 

  3. Holtan SG, Pasquini M, Weisdorf DJ . Acute graft-versus-host disease: a bench-to-bedside update. Blood 2014; 124: 363–373.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Blazar BR, Murphy WJ, Abedi M . Advances in graft-versus-host disease biology and therapy. Nat Rev Immunol 2012; 12: 443–458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Koyama M, Kuns RD, Olver SD, Raffelt NC, Wilson YA, Don AL et al. Recipient nonhematopoietic antigen-presenting cells are sufficient to induce lethal acute graft-versus-host disease. Nat Med 2011; 18: 135–142.

    Article  PubMed  Google Scholar 

  6. Tichelli A, Gratwohl A . Vascular endothelium as 'novel' target of graft-versus-host disease. Best Pract Res Clin Haematol 2008; 21: 139–148.

    Article  CAS  PubMed  Google Scholar 

  7. MacMillan ML, Weisdorf DJ, Wagner JE, DeFor TE, Burns LJ, Ramsay NK et al. Response of 443 patients to steroids as primary therapy for acute graft-versus-host disease: comparison of grading systems. Biol Blood Marrow Transplant 2002; 8: 387–394.

    Article  CAS  PubMed  Google Scholar 

  8. Westin JR, Saliba RM, De Lima M, Alousi A, Hosing C, Qazilbash MH et al. Steroid-refractory acute GVHD: predictors and outcomes. Adv Hematol 2011; 2011: 601953.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Remberger M, Kumlien G, Aschan J, Barkholt L, Hentschke P, Ljungman P et al. Risk factors for moderate-to-severe chronic graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2002; 8: 674–682.

    Article  PubMed  Google Scholar 

  10. Almici C, Skert C, Verardi R, Di Palma A, Bianchetti A, Neva A et al. Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease. Transplantation 2014; 98: 706–712.

    Article  CAS  PubMed  Google Scholar 

  11. Snover DC, Weisdorf SA, Ramsay NK, McGlave P, Kersey JH . Hepatic graft versus host disease: a study of the predictive value of liver biopsy in diagnosis. Hepatology 1984; 4: 123–130.

    Article  CAS  PubMed  Google Scholar 

  12. Dumler JS, Beschorner WE, Farmer ER, Di Gennaro KA, Saral R, Santos GW . Endothelial-cell injury in cutaneous acute graft-versus-host disease. Am J Pathol 1989; 135: 1097–1103.

    CAS  PubMed  PubMed Central  Google Scholar 

  13. MacMillan ML, DeFor TE, Weisdorf DJ . The best endpoint for acute GVHD treatment trials. Blood 2010; 115: 5412–5417.

    Article  CAS  PubMed  Google Scholar 

  14. Inamoto Y, Martin PJ, Storer BE, Mielcarek M, Storb RF, Carpenter PA . Response endpoints and failure-free survival after initial treatment for acute graft-versus-host disease. Haematologica 2014; 99: 385–391.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant 2015; 21: 761–767.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Sorror ML, Martin PJ, Storb RF, Bhatia S, Maziarz RT, Pulsipher MA et al. Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. Blood 2014; 124: 287–295.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Kim DH, Lee NY, Lee MH, Sohn SK . Vascular endothelial growth factor gene polymorphisms may predict the risk of acute graft-versus-host disease following allogeneic transplantation: preventive effect of vascular endothelial growth factor gene on acute graft-versus-host disease. Biol Blood Marrow Transplant 2008; 14: 1408–1416.

    Article  CAS  PubMed  Google Scholar 

  18. Holtan SG, Verneris MR, Schultz KR, Newell LF, Meyers G, He F et al. Circulating angiogenic factors associated with response and survival in patients with acute graft-versus-host disease: results from Blood and Marrow Transplant Clinical Trials Network 0302 and 0802. Biol Blood Marrow Transplant 2015; 21: 1029–1036.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A et al. Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system. Blood 2011; 118: 1685–1692.

    Article  CAS  PubMed  Google Scholar 

  20. Andrulis M, Dietrich S, Longerich T, Koschny R, Burian M, Schmitt-Graf A et al. Loss of endothelial thrombomodulin predicts response to steroid therapy and survival in acute intestinal graft-versus-host disease. Haematologica 2012; 97: 1674–1677.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Rachakonda SP, Penack O, Dietrich S, Blau O, Blau IW, Radujkovic A et al. Single-nucleotide polymorphisms within the thrombomodulin gene (THBD) predict mortality in patients with graft-versus-host disease. J Clin Oncol 2014; 32: 3421–3427.

    Article  PubMed  Google Scholar 

  22. Jenq RR, Taur Y, Devlin SM, Ponce DM, Goldberg JD, Ahr KF et al. Intestinal blautia is associated with reduced death from graft-versus-host disease. Biol Blood Marrow Transplant 2015; 21: 1373–1383.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Atkinson K, Farrell C, Chapman G, Downs K, Penny R, Biggs J . Female marrow donors increase the risk of acute graft-versus-host disease: effect of donor age and parity and analysis of cell subpopulations in the donor marrow inoculum. Br J Haematol 1986; 63: 231–239.

    Article  CAS  PubMed  Google Scholar 

  24. MacMillan ML, DeFor TE, Weisdorf DJ . What predicts high risk acute graft-versus-host disease (GVHD) at onset?: identification of those at highest risk by a novel acute GVHD risk score. Br J Haematol 2012; 157: 732–741.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Paczesny S, Levine JE, Braun TM, Ferrara JL . Plasma biomarkers in graft-versus-host disease: a new era? Biol Blood Marrow Transplant 2009; 15: 33–38.

    Article  PubMed  Google Scholar 

  26. Srinivasan R, Daniels J, Fusaro V, Lundqvist A, Killian JK, Geho D et al. Accurate diagnosis of acute graft-versus-host disease using serum proteomic pattern analysis. Exp Hematol 2006; 34: 796–801.

    Article  CAS  PubMed  Google Scholar 

  27. Wang H, Clouthier SG, Galchev V, Misek DE, Duffner U, Min CK et al. Intact-protein-based high-resolution three-dimensional quantitative analysis system for proteome profiling of biological fluids. Mol Cell Proteomics 2005; 4: 618–625.

    Article  CAS  PubMed  Google Scholar 

  28. Levine JE, Braun TM, Harris AC, Holler E, Taylor A, Miller H et al. A prognostic score for acute graft-versus-host disease based on biomarkers: a multicentre study. Lancet Haematol 2015; 2: e21–e29.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Lee KH, Choi SJ, Lee JH, Lee JS, Kim WK, Lee KB et al. Prognostic factors identifiable at the time of onset of acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. Haematologica 2005; 90: 939–948.

    PubMed  Google Scholar 

  30. Ayuk F, Bussmann L, Zabelina T, Veit R, Alchalby H, Wolschke C et al. Serum albumin level predicts survival of patients with gastrointestinal acute graft-versus-host disease after allogeneic stem cell transplantation. Ann Hematol 2014; 93: 855–861.

    Article  CAS  PubMed  Google Scholar 

  31. Thoma MD, Glejf J, Jacob E, Huneke TJ, DeCook LJ, Johnson ND et al. Impact of clinical factors and allograft leukocyte content on post-transplant lymphopenia, monocytopenia, and survival in patients undergoing allogeneic peripheral blood haematopoietic cell transplant. BMC Hematol 2014; 14: 14.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS . Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008; 27: 157–172; discussion 207-12.

    Article  PubMed  Google Scholar 

  33. Rowlings PA, Przepiorka D, Klein JP, Gale RP, Passweg JR, Henslee-Downey PJ et al. IBMTR Severity Index for grading acute graft-versus-host disease: retrospective comparison with Glucksberg grade. Br J Haematol 1997; 97: 855–864.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work is supported in part by the Masonic Cancer Center, University of Minnesota.

Author information

Authors and Affiliations

  1. Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, MN, USA,

    S G Holtan & M L MacMillan

  2. Department of Medicine, University of Minnesota, Minneapolis, MN, USA

    S G Holtan

  3. Department of Pediatrics, University of Minnesota, Minneapolis, MN, USA

    M L MacMillan

Authors
  1. S G Holtan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M L MacMillan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to S G Holtan.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Holtan, S., MacMillan, M. A risk-adapted approach to acute GVHD treatment: are we there yet?. Bone Marrow Transplant 51, 172–175 (2016). https://doi.org/10.1038/bmt.2015.261

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2015.261

This article is cited by

Search

Advanced search

Quick links